Iza-Bren
Iza-Bren (BL-B01D1): Bispecific EGFR/HER3 ADC Shows Promise in EGFR-Mutated NSCLC
Iza-Bren (BL-B01D1) is a bispecific EGFR/HER3 ADC for EGFR-mutated NSCLC. At IASLC WCLC 2025, Phase II combo with osimertinib showed 100% ORR and 92% 12-mo PFS; monotherapy in pretreated patients had 66% ORR and 80% 12-mo OS, with manageable safety.